Philips agrees to acquire SpectraWAVE Inc., advancing next-generation coronary intravascular imaging and physiological assessment with AI December 15, 2025 Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled angio-based FFR technology that delivers rapid, accurate coronary physiology assessment from a single angiogram [1] SpectraWAVE’s technologies have the potential to significantly increase adoption of corona...
Philips reiterates timing of 2026 outlook December 4, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today reaffirmed that its 2026 outlook will be issued as planned on February 10, in line with the company’s previously communicated schedule. As previously guided, the company expects continued performance improvement with sequential comparable sales growth, expanded margins (despite tariff headwinds) and strong cashflow. The company continues to expect comparative sales growth to accelerate sequentially in 2026 towards mid-single-digit gro...
Philips expands commercial availability of world’s first real-time AI-enabled light-based 3D navigation solution for image-guided therapy December 1, 2025 Commercial availability expanded across Europe and the United StatesReal-time AI-enabled 3D device visualization powered by light instead of X-ray, improving navigation in complex endovascular proceduresLumiGuide seamlessly integrates with Azurion, Philips’ proven, world-leading image-guided therapy platform designed to drive procedural innovation across clinical domains Amsterdam, the Netherlands and Chicago, USA – (NYSE: PHG, AEX: PH...
Philips launches Verida, world’s first detector-based spectral CT powered by breakthrough AI, to advance diagnostic precision November 30, 2025 Philips pioneered detector-based spectral CT, which has been widely adopted in clinical routine exams across anatomies, supported by over 800 peer-reviewed publications [1]CE-marked, 510k pending Verida CT [2] integrates AI across the imaging chain, providing superb image quality while accelerating workflow and reducing dose [3, 4] Amsterdam, the Netherlands and Chicago, USA – At RSNA 2025, (NYSE: PHG, AEX: PHIA), a global leader in health techno...
Philips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MRI platform November 30, 2025 Major technology breakthrough combines advanced AI for clinical insights and accelerated workflow in new premium 3.0T MRI platform [1] Amsterdam, the Netherlands, and Chicago, USA – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today unveiled BlueSeal Horizon [1], an entirely new 3.0T MRI innovation platform that includes the industry’s first helium-free 3.0T magnet at . A pivotal advance in MRI innovation, helium-free [2] 3.0T is a major scientific achievement set to have s...
Philips launches next-generation web-based diagnostic viewer for fast, secure imaging data access anywhere November 24, 2025 New viewer offers full radiology capabilities, interfaces with AI and interactive reporting module to streamline workflows Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Philips Image Management 15, the next generation of Philips Vue PACS, including a zero-footprint, [1] that transforms how radiologists access and interpret medical images. Designed with a brand-new user interface, the viewe...
Philips and Cortechs.ai extend partnership to advance quantitative neuroimaging and strengthen Philips’ leadership in precision diagnostics in neurology November 19, 2025Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced an extended partnership with , a pioneer in quantitative neuroimaging solutions. Together, the companies will integrate Cortechs.ai’s advanced AI-enabled neuroimaging analytics directly into Philips’ MR systems [1], empowering clinicians with faster, more objective, and reproducible insights into brain health. The col...
Philips reported a better-than-expected 3Q25 update although with mixed underlying quality. We have limited changes to estimates and reiterate our €23/share target price and Hold rating. We believe valuation is fair relative to peers given Philips' lower growth and margin profile.
Philips brings AI into the procedure room to assist doctors during heart valve repair November 17, 2025Innovation uses AI to track and visualize tiny repair devices* through the beating heart, helping clinicians navigate in 3D with enhanced clarity and confidence**Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced DeviceGuide, an AI-powered device tracking* solution that assists physicians during one of interventional cardiology’s most technically demanding procedures: repairing leaking heart valves through a minimally invasive appr...
3Q'25 vs. 3Q'24 Results Rental Revenues: € 98.7 M (-3.0% vs. -3.7% BS(e)); EBITDA: € 83.6 M (-3.8% vs. -3.3% BS(e)); Recurring EPS: € 0.08 M (-12.5% vs. -11.2% BS(e)); 9M'25 vs. 9M'24 Results Rental Revenues: € 295.7 M (+1.0% vs. +0.8% BS(e)); EBITDA: € 242.6 M (+1.1% vs. +1.3% BS(e)); Recurring EPS: € 0.25 M (-3.9% vs. -3.5% BS(e));
Rdos. 3T'25 vs 3T'24: Ingresos por rentas: 98,7 M euros (-3,0% vs -3,7% BS(e)); EBITDA: 83,6 M euros (-3,8% vs -3,3% BS(e)); BPA recurrente: 0,08 euros (-12,5% vs -11,2% BS(e)). Rdos. 9meses'25 vs 9meses'24: Ingresos por rentas: 295,7 M euros (+1,0% vs +0,8% BS(e)); EBITDA: 242,6 M euros (+1,1% vs +1,3% BS(e)); BPA recurrente: 0,25 euros (-3,9% vs -3,5% BS(e)).
NEWS SUMMARY: ACCIONA, ACCIONA ENERGÍA, ACS, AENA, COLONIAL, ELECTRICITY SECTOR, MERLIN, REPSOL, SANTANDER, TALGO. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 3Q’25 results to be released over the coming days in Spain. Markets see profit taking European stock markets ended up with profit taking in a session that ended worse than it began in a technical movement to digest th...
El comportamiento operativo tanto de COL como de MRL (ocupación y rentas), sigue siendo positivo y esperamos que continúe siéndolo a futuro, aunque por distintos motivos. En el caso de MRL (100% de exposición a Iberia) la macro está apoyando el crecimiento de la demanda. Por su parte, COL, con mucha exposición a París, donde apenas hay crecimiento económico, se está beneficiando de la escasez de producto superprime. En ambos casos, y especialmente en MRL, la cartera de activos en desarrollo (pip...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.